NEPHRITOGENIC ACTIVITY OF IgA-BINDING STREPTOCOCCUS PYOGENES: AN EXPERIMENTAL MODEL OF IgA GLOMERULONEPHRITIS
https://doi.org/10.15789/1563-0625-2016-3-221-230
Abstract
The aim of present study was to arrange an experimental rabbit model for IgA-nephropathy. To this purpose, an approach was attempted which was previously successfully applied in rabbits, aiming for induction of post-streptococcal glomerulonephritis (PSGN). To induce the nephropathy, we used two Streptococcus pyogenes strains of M4 and M60 serotypes which showed differential IgA-binding capacity mediated by the IgAFc microbial receptors. The renal tissue damage was developed in most animals treated with emm60 S. pyogenes characterized by marked IgAFcR expression and higher IgA-binding ability. By means of morphometric analysis. Significant morphological and immunochemical glomerular changes were revealed in 6/10 rabbits, as follows: (i) massive IgA deposition in the mesangial glomerular cells, atrophy of the capillary net, and tissue oedema; (ii) marked C3-complement deposition in proximal and distal tubules; (iii) a significant infiltration of cortical and medullar areas by lymphocytes associated with weak TNFα production. Noteworthy, we did not observe local IgG deposition in any cases, thus allowing to exclude any role of anti-IgG, or other IgG’s in evolution of the pathology. Alternatively, the IgA-deposits may occur due to microbial IgA FcR–IgAcontaining cоmplexes, as earlier shown by the Swedish scientists. The above tissue changes were completely absent in kidneys of control animals. Taken together, these data suggest that we have developed an experimental model similar to IgA-nephropathy in humans. The results also extend our knowledge on pathogenic effects of the IgA Fc-binding proteins of Streptococcus pyogenes.
About the Authors
L. A. Burova
Institute of Experimental Medicine, St. Petersburg, Russian Federation
Russian Federation
Russian Federation
PhD, MD (Medicine), Leading Research Associate, Department of Molecular Microbiology
P. V. Pigarevsky
Institute of Experimental Medicine, St. Petersburg, Russian Federation
Russian Federation
Russian Federation
PhD (Biology), Head, Department of General Morphology
V. A. Snegova
Institute of Experimental Medicine, St. Petersburg, Russian Federation
Russian Federation
Russian Federation
Research Associate, Department of General Morphology
N. V. Duplik
Institute of Experimental Medicine, St. Petersburg, Russian Federation
Russian Federation
Russian Federation
PhD (Biology), Research Associate, Department of Molecular Microbiology
Klaas Schalen
Department of Medical Microbiology, Lund University, Lund, Sweden
Russian Federation
Russian Federation
PhD, MD (Medicine), Department of Medical Microbiology
Artem A. Totolian
Institute of Experimental Medicine, St. Petersburg, Russian Federation
Russian Federation
Russian Federation
PhD, MD (Medicine), Academician, Russian Academy of Sciences, Main Research Associate, Department of Molecular Microbiology 197376, Russian Federation, St. Petersburg, Acad. Pavlov str, 12. Phone: 7 (812) 234-68-74
References
1. Нефрология (Руководство для врачей) под редакцией И.Е.Тареевой. М.: Медицина, 1995. В 2-х томах. [Nephrology (A guide for physicians in 2 volumes. (Editor I.E.Tareeva)]. Moscow: Meditsina, 1995.
2. Barratt J., Smith A.C., Feehally J. The pathogenic role of IgA1 O-linked glycosylation in the pathogenesis of IgA nephropathy. Nephrology (Carlton), 2007, Vol. 12, no. 3, pp. 275-284.
3. Berthelot L., Papista C., Maciel T.T., Biarnes-Pelicot M., Tissandie E., Wang P.H., Tamouza H., Jamin A., Bex-Coudrat J., Gestin A., Boumediene A., Arcos-Fajardo M., England P., Pillebout E., Walker F., Daugas E., Vrtosvnik F., Flamant M., Benhamou M., Cogné M., Moura I.C., Monteiro R.C. Transglutaminase is essential for IgA nephropathy development acting through IgA receptors. J. Exp. Med., 2012, Vol. 209, no. 4, pp. 793-806.
4. Berthelot L., Monteiro R.C. Formation of IgA deposits in Berger’s disease: what we learned from animal models. Biol. Aujourd’hui, 2013, Vol. 207, no. 4, pp. 241-247.
5. Boyd J.K., Cheung C.K, Molyneux K., Feehally J., Barratt J. An update on the pathogenesis and treatment of IgA nephropathy. Kidney International, 2012, Vol. 81, pp. 833-843.
6. Burova L., Thern A., Pigarevsky P., Seliverstova V., Gavrilova E., Nagornev V., Schalen C., Totolian A. Role of group A streptococcal IgG-binding protein in triggering experimental glomerulonephritis in the rabbit. APMIS, 2003, Vol. 111, pp. 955-962.
7. Burova L., Pigarevsky P., Seliverstova V., Gupalova T., Schalen C., Totolian A. Experimental poststreptococcal glomerulonephritis elicited by IgGFc-binding M family proteins and blocked by IgG Fc fragment. APMIS, 2012, Vol. 120, no. 3, pp. 221-230.
8. Collan Y. Morphometry in pathology: another look at diagnostic histopathology. Pathol. Res. Pract., 1984, Vol. 1, pp. 189-192.
9. Coppo R. The pathogenetic potential of environmental antigens in IgA nephropathy. Am. J. Kidney Dis., 1988, Vol. 12, no. 5, pp. 420-424.
10. Coppo R. The intestine-renal connection in IgA nephropathy. Nephrol. Dial. Transplant., 2015, Vol. 30, no. 3, pp. 360-366.
11. Hashimoto A., Suzuki Y., Suzuki H., Ohsawa I., Brown R., Hall S., Tanaka Y., Novak J., Ohi H., Tomino H. Determination of severity of murine IgA nephropathy by glomerular complement activation by aberrantly glycosylated IgA and immune complexes. Am. J. Pathol., 2012, Vol. 181, no. 4, pp. 1338-1347.
12. Jessen R.H., Emancipator S.N., Jacobs G.H., Nedrud J.G. Experimental IgA-IgG nephropathy induced by a viral respiratory pathogen. Dependence on antigen form and immune status. Lab. Invest., 1992, Vol. 67, no. 3, pp. 379-386.
13. Kovalenko P., Fujinaka H., Yoshida Y., Kawamura H., Qu Z., El-Shemi A., Li H., Matsuki A., Bilim V., Yaoita E., Abo T., Uchiyama M., Yamamoto T. Fc receptor-mediated accumulation of macrophages in crescentic glomerulonephritis induced by antiglomerular basement membrane antibody administration in WKY rats. International Immunology, 2004, Vol. 16, no. 5, pp. 625-634.
14. Liu H., Peng Y., Liu F., Xiao W., Zhang Y., Li W. Expression of IgA class switching gene in tonsillar mononuclear cells in patients with IgA nephropathy. Inflamm Res., 2011, Vol. 60, no. 9, pp. 869-878.
15. Meng H., Ohtake H., Ishida A., Ohta N., Kakehata S., Yamakawa M. IgA production and tonsillar focal infection in IgA nephropathy. J. Clin. Exp. Hematop., 2012, Vol. 52, no. 3, pp. 161-170.
16. Nakata J., Suzuki Y., Suzuki H., Sato D., Kano T., Yanagawa H., Matsuzaki K., Horikoshi S., Novak J., Tomino Y. Changes in nephritogenic serum galactose-deficient IgA1 in IgA nephropathy following tonsillectomy and steroid therapy. PloS One, 2014, Vol. 9, no. 2, e89707.
17. Okazaki K., Suzuki Y., Otsuji M., Suzuki H., Kihara M., Kajiyama T., Hashimoto A., Nishimura H., Brown R., Hall S., Novak J., Izui S., Hirose S., Tomino Y. Development of a model of early-onset IgA nephropathy. J. Am. Soc. Nephrol., 2012, Vol. 23, no. 8, pp. 1364-1374.
18. Piccolo M., De Angelis M., Lauriero G., Montemurno E., Di Cagno R., Gobbetti M. Salivary Microbiota associated with immunoglobulin A. Nephropathy. Microb. Ecol., 2015, Vol. 70, no. 2, pp. 557-565.
19. Schmitt R., Carlsson F., Mörgelin M., Tati R., Lindahl G., Karpman D. Tissue deposits of IgA-binding streptococcal M proteins in IgA nephropathy and Henoch-Schonlein purpura. Am. J. Pathol., 2010, Vol. 176, no. 2, pp. 608-618.
20. Schmitt R., Ståhl A., Olin A., Kristoffersson A.-C., Rebetz A., Novak J., Lindahl G., Karpman D. The combined role of galactose-deficient IgA1 and Streptococcal IgA-binding M protein in inducing IL-6 and C3 secretion from human mesangial cells: Implications for IgA nephropathy. J. Immunol., 2014, Vol. 193, no. 1, pp. 317-326.
21. Stenberg L., O’Toole P., Lindahl G. Many group A streptococcal strains express two different immunoglobulin-binding proteins, encoded by closely linked genes: characterization of the proteins expressed by four strains of different M-type. Molecular Microbiology, 1992, Vol. 6, no. 9, pp. 1185- 1194.
22. Suzuki H., Run Fan, Zhixin Zhang, Brown R., Hall S., Bruce A.J., Chatham W.W., Suzuki Y., Wyatt R.J.,
23. Moldoveanu Z., Lee J.Y., Robinson J., Tomana M., Tomino Y., Mestecky J., Novak J. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J. Clin. Invest., 2009, Vol. 119, no. 6, pp. 1668-1677.
24. Suzuki H., Kiryluk K., Novak J., Moldoveanu Z., Herr A.B., Renfrow M.B., Wyatt R.J., Scolari F., Mestecky J., Gharavi A.G., Bruce A.J. The pathophysiology of IgA nephropathy. J. Am. Soc. Nephrol., 2011, Vol. 22, pp. 1795-1803.
25. Suzuki H., Suzuki Y., Novak J., Tomino Y. Development of animal models of human IgA nephropathy. Drug Discov. Today Dis. Models, 2014, Vol. 11, pp. 5-11.
26. Tanaka M., Seki G., Someya T., Nagata M., Fujita T. Aberrantly glycosylated IgA1 as a factor in the pathogenesis of IgA nephropathy. Clin. Dev. Immunol., 2011, Vol. 2011, ID 470803.
27. Tian J., Wang Y., Zhou X., Li Y., Wang C., Li J., Li R. Rapamycin slows IgA nephropathy progression in the rat. Am. J. Nephrol., 2014, Vol 39. no. 3, pp. 218-229.
28. Tomana M., Matousovic K., Julian B.A., Radl J., Konecny K., Mestecky J. Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG. Kidney Int., 1997, Vol. 52, no. 2, pp. 509-516.
29. Wyatt R.J., Bruce A.J. IgA Nephropathy. N. Engl. J. Med., 2013, Vol. 368, pp. 202-214.
Review
For citations:
Burova L.A., Pigarevsky P.V., Snegova V.A., Duplik N.V., Schalen K., Totolian A.A. NEPHRITOGENIC ACTIVITY OF IgA-BINDING STREPTOCOCCUS PYOGENES: AN EXPERIMENTAL MODEL OF IgA GLOMERULONEPHRITIS. Medical Immunology (Russia). 2016;18(3):221-230. (In Russ.) https://doi.org/10.15789/1563-0625-2016-3-221-230
Views:
630
Email this article 